Vesna Brglez

Vesna Brglez

Auto-generated profile, based on publicly available information

Vesna Brglez

Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Nice, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDaniel Re
Daniel Re
BSBarbara Seitz-Polski
Barbara Seitz-Polski
VBVesna Brglez
Vesna Brglez
MCMichel Carles
Michel Carles
DGDaisy Graça
Daisy Graça
JBJérôme Barrière
Jérôme Barrière
Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure.

1 December 2014 in Biochimie
Verified
Journal Article
Closed access
VBVesna Brglez
Vesna Brglez
GLGerard Lambeau
Gerard Lambeau
TPToni Petan
Toni Petan

27 September 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
APAnja Pucer
Anja Pucer
VBVesna Brglez
Vesna Brglez
CPChristine Payré
Christine Payré
JPJože Pungerčar
Jože Pungerčar
GLGerard Lambeau
Gerard Lambeau
TPToni Petan
Toni Petan
Background: Alterations in lipid metabolism are inherent to the metabolic transformations that support tumorigenesis. The relationship between the synthesis, storage and use of lipids and their importance in cancer is poorly understood. The human group X secreted phospholipase A2 (hGX sPLA2) releases fatty acids (FAs) from cell membranes and lipoproteins, but its involvement in the regulation of cellular FA metabolism and cancer is not known. Results: Here we demonstrate that hGX sPLA2 induces lipid droplet (LD) formation in invasive breast cancer cells, stimulates their proliferation and prevents their death on serum deprivation. The effects of hGX sPLA2 are shown to be dependent on its enzymatic activity, are mimicked by oleic acid and include activation of protein kinase B/Akt, a cell survival signaling kinase. The hGX sPLA2-stimulated LD biogenesis is accompanied by AMP-activated protein kinase (AMPK) activation, up-regulation of FA oxidation enzymes and the LD-coating protein perilipin 2, and suppression of lipogenic gene expression. Prolonged activation of AMPK inhibited hGX sPLA2-induced LD formation, while etomoxir, an inhibitor of FA oxidation, abrogated both LD formation and cell survival. The hGX sPLA2-induced changes in lipid metabolism provide a minimal immediate proliferative advantage during growth under optimal conditions, but they confer to the breast cancer cells a sustained ability to resist apoptosis during nutrient and growth factor limitation. Conclusion: Our results identify hGX sPLA2 as a novel modulator of lipid metabolism that promotes breast cancer cell growth and survival by stimulating LD formation and FA oxidation.

29 October 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SHSamuel Hernandez‐Anzaldo
Samuel Hernandez‐Anzaldo
EBEvan Berry
Evan Berry
VBVesna Brglez
Vesna Brglez
DLDickson Leung
Dickson Leung
TYTae Jin Yun
Tae Jin Yun
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
Background: Endocrine functions of the heart have been well established. We investigated the hypothesis that cardiac secretion of a unique phospholipase A 2 recently identified by our laboratory (cardiac secreted phospholipase A 2 [ sPLA 2 ]) establishes a heart–liver endocrine axis that is negatively regulated by matrix metalloproteinase‐2 (MMP‐2). Methods and Results: In Mmp2 −/− mice, cardiac (but not hepatic) sPLA 2 was elevated, leading to hepatic inflammation, immune cell infiltration, dysregulation of the sterol regulatory element binding protein‐2 and liver X receptor‐α pathways, abnormal transcriptional responses to dietary cholesterol, and elevated triglycerides in very low‐density lipoprotein and in the liver. Expression of monocyte chemoattractant protein‐3, a known MMP‐2 substrate, was elevated at both mRNA and protein levels in the heart. Functional studies including in vivo antibody neutralization identified cardiac monocyte chemoattractant protein 3 as a possible agonist of cardiac sPLA 2 secretion. Conversely, systemic sPLA 2 inhibition almost fully normalized the cardiohepatic phenotype without affecting monocyte chemoattractant protein‐3. Finally, wild‐type mice that received h igh‐performance liquid chromatography –isolated cardiac sPLA 2 from Mmp2 −/− donors developed a cardiohepatic gene expression profile similar to that of Mmp2 −/− mice. Conclusions: These findings identified the novel MMP‐2/cardiac sPLA 2 pathway that endows the heart with important endocrine functions, including regulation of inflammation and lipid metabolism in the liver. Our findings could also help explain how MMP 2 deficiency leads to cardiac problems, inflammation, and metabolic dysregulation in patients.

1 February 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
VBVesna Brglez
Vesna Brglez
APAnja Pucer
Anja Pucer
JPJože Pungerčar
Jože Pungerčar
GLGerard Lambeau
Gerard Lambeau
TPToni Petan
Toni Petan

1 January 2021 in Clinical Biochemistry
Verified
Journal Article
Closed access
ATAurélie Truffot
Aurélie Truffot
JJJean-François Jourdil
Jean-François Jourdil
BSBarbara Seitz-Polski
Barbara Seitz-Polski
PMPaolo Malvezzi
Paolo Malvezzi
VBVesna Brglez
Vesna Brglez
EGElodie GAUTIER-VEYRET
Elodie GAUTIER-VEYRET